Get all your news in one place.

100’s of premium titles.
One app.

Get all your news in one place.

100’s of premium titles. One news app.

The Latest Breaking News from Cigna

Investors who are seeking the highest — but safest — yields possible eventually compare real estate investment trusts (REITs) with bonds. This is especially true for retirees who want to make the most of their retirement funds. They want the highest yields possible, but they don’t want to risk their…

Benzinga

The $18,000 breast biopsy

The hospital estimated the biopsy would cost $1,400. How did it end up being so much more, even with insurance?

Salon

10 Companies Raise Their Juicy Dividends Like Crazy

What's better than a big fat S&P 500 dividend? One that's rising fast. And there's a surprising number of S&P 500 stocks doing it.

Investors Business Daily

From analysis to the latest developments in health,
read the most diverse news in one place.

Dow Jones Futures: Nasdaq Extends Losing Streak; Apple iPhone 14 On Call

The Nasdaq extended its losing streak Tuesday, with the Apple iPhone 14 on tap. Enphase Energy leads 5 relative winners.

Investors Business Daily

5 Dividend Stocks to Buy and Hold Forever

Persistent economic turbulence and an uncertain outlook have led investors to prioritize steady income generation from their investments. Hence, fundamentally sound dividend yielders with a solid track record and potential for perpetual growth Merck (MRK), Abbott (ABT), Cigna (CI), Energy Transfer (ET), and Kronos (KRO) could be permanent additions to…

StockNews.com

Check Out What Whales Are Doing With Cigna

A whale with a lot of money to spend has taken a noticeably bearish stance on Cigna. Looking at options history for Cigna (NYSE:CI) we detected 15 strange trades.

Benzinga

The $18,000 breast biopsy: When having insurance costs you a bundle

When Dani Yuengling felt a lump in her right breast last summer, she tried to ignore it.

Tribune News Service

Read news from The Economist, FT, and more,
with one subscription

An $18,000 biopsy? Paying cash might have been cheaper than using her insurance

A hospital's cost calculator said her procedure would be $1,400 for patients without insurance. Instead, the bill was almost $18,000 and, her part was more than $5,000 — the balance of her deductible.

WEKU

What Are Whales Doing With Cigna

Someone with a lot of money to spend has taken a bearish stance on Cigna (NYSE:CI). And retail traders should know. We noticed this today when the big position showed up on publicly available options history that we track here at Benzinga.

Benzinga

Humana Dips After Huge Earnings Beat; Centene Is Better Than Recession-Proof

Humana earnings flew past estimates, following Centene's Q2 beat. Centene's outlook may be even brighter if there's a recession.

Investors Business Daily

Looking At Cigna's Recent Whale Trades

A whale with a lot of money to spend has taken a noticeably bearish stance on Cigna. Looking at options history for Cigna (NYSE:CI) we detected 13 strange trades.

Benzinga

Inside IBD 50: Breakout Stocks Struggle To Get Airborne

Several IBD 50 stocks that have recently broken out of bases are struggling to advance amid a sluggish overall market.

Investors Business Daily

UnitedHealth Earnings Beat; UNH Stock Clears Buy Point

UnitedHealth earnings easily beat Q2 estimates and raised guidance. UNH stock moved above a buy point.

Investors Business Daily

Looking At Cigna's Recent Whale Trades

A whale with a lot of money to spend has taken a noticeably bearish stance on Cigna. Looking at options history for Cigna (NYSE:CI) we detected 11 strange trades.

Benzinga

Get all your
news in one place.

100’s of premium titles.
One news app.

Investors Business Daily

Stock Market Indexes Tumble Nearly 2% After Another Hot Inflation Report; Bank Earnings Disappoint

The producer price index jumped 11.3% in June from the same period a year ago.

Investors Business Daily

Dow Jones Higher, Nasdaq Tests This Potential Resistance Level; These IBD 50 Stocks Hit Buy Points

The Nasdaq gained over 2% on Thursday and is attempting to regain its 50-day line.

Investors Business Daily

Stock Market Indexes See More Green As Health Care Stocks Hit Buy Points

The major stock market indexes are near the highs of the day at midday.

Benzinga

Here's How Much You Would Have Made Owning Cigna Stock In The Last 10 Years

Cigna (NYSE:CI) has outperformed the market over the past 10 years by 9.15% on an annualized basis producing an average annual return of 20.13%. Currently, Cigna has a market capitalization of $84.90 billion.

Get all your
news in one place.

100’s of premium titles.
One news app.

Benzinga

Morgan Stanley Upgrades Cigna On Humira Prospects

Cigna Corp (NYSE: CI) is poised to benefit from the launch of bioequivalent Humira in July 2023, according to Morgan Stanley.

Benzinga

Benzinga's Top Ratings Upgrades, Downgrades For June 22, 2022

Upgrades

StockNews.com

3 Attractive 'Growth at a Reasonable Price' Stocks to Buy Now

GARP is a strategy to blend the best parts of value and growth investing. It's particularly apt as it will allow investors to identify the top growth stocks trading at attractive valuations such as Cigna (CI), Freeport McMoran (FCX), and Micron (MU).

Benzinga

What 15 Analyst Ratings Have To Say About Cigna

Within the last quarter, Cigna (NYSE:CI) has observed the following analyst ratings:

Salon

Oz profits from insulin price gougers

Mehmet Oz specifically called out UnitedHealth and CVS for soaring prices — but he's heavily invested in both

StockNews.com

3 Attractive 'Growth at a Reasonable Price' Stocks to Buy Now

Growth stocks have been mired in a brutal bear market. However, a handful of stocks are quite cheap and continue to grow at an impressive rate. 3 such stocks that investors should consider buying are Cigna (CI), Micron (MU), and Freeport McMoran (FCX).

Tribune News Service

Federal regulators probe Cigna’s pharmacy benefit manager, CVS Caremark, and others. What are they investigating?

Express Scripts, the pharmacy benefit manager that Cigna Corp. bought in 2018, is being investigated by the Federal Trade Commission for what regulators claim is influence over drug prices wielded by pharmacy benefit managers and transparent business practices.

1 … 3 4 5 6

People

From analysis to the latest developments in health,
read the most diverse news in one place.

Organisations

SP Global Market Intelligence

Read news from The Economist, FT, and more,
with one subscription

Topics

Places

Fourteen days free

Download the app

One app. One membership.
100+ trusted global sources.